Formulation and Evaluation of Transdermal Patches Containing Glimipiride

Abstract

The purpose of this research was to develop a matrix-type transdermal therapeutic system containing drug Glimepride with different ratios of hydrophilic and hydrophobic polymeric systems by the solvent evaporation technique. Different concentrations of oleic acid and isopropyle myristate were used to enhance the transdermal permeation of glimipride. Matrix type transdermal patches prepared by using different ratio of Eudragit RS100, HPMC100M, by using solvent evaporation techniques. All the prepared formulation were subjected to evaluation studies i.e., weight variation, thickness, drug content, moisture content, moisture uptake, flatness and in-vitro drug release. The physicochemical compatibility of the drug and the polymers studied by differential scanning calorimetry and infrared spectroscopy suggested absence of any incompatibility. Compatibility study between drug and polymer can be done by FTIR. From the all formulation batch F3 was optimized formula. Shows linear zero order release for 24 hrs with cumulative % drug diffusion of 88.34% from 4cm2 patches. It is concluded that concentration of polymer (HPMC100M) when increases into primary layer, then In-vitro diffusion rate also increases and concentration of Eudragit Rs100 when increases, the drug diffusion decreases. It provides better controlled drug release for patch.